Wednesday, July 8, 2026

Patent intelligence · US

US 7452866

Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1

granted A61KA61K38/04A61K38/1709
Status granted
Linked drugs 1
Pipeline programs 6
Years to expiry 2
Applicant portfolio 36
Patent details — US 7452866

Quick answer

US 7452866 (Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1) is held by Alseres Pharmaceuticals, Inc.. Status: granted. Granted Nov 18, 2008. Expires Nov 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Key facts

Grant date
Expiration
Claims
17
CPC classes
A61K, A61K38/04, A61K38/1709

More from Alseres Pharmaceuticals, Inc.

Related pharmaceutical patents in our USPTO index.

  1. US 12409197

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Sep 4, 2045

    granted
  2. US 12214002

    Compositions and methods for treating antibiotic resistance

    Seres Therapeutics, Inc. · Expires Jan 30, 2045

    granted
  3. US 12083151

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Sep 5, 2044

    granted
  4. US 11918612

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Feb 29, 2044

    granted
  5. US 11730775

    Methods for treatment of Clostridium difficile infection or recurrence or symptoms thereof

    Seres Therapeutics, Inc. · Expires Aug 17, 2043

    granted
  6. US 11701394

    Compositions and methods for treating cholestatic disease

    Seres Therapeutics, Inc. · Expires Jul 13, 2043

    granted
  7. US 11666612

    Network-based microbial compositions and methods

    Seres Therapeutics, Inc. · Expires Jun 1, 2043

    granted
  8. US 11464812

    Synergistic bacterial compositions and methods of production and use thereof

    Seres Therapeutics, Inc. · Expires Oct 6, 2042

    granted

Frequently asked questions

What is US patent 7452866?

US 7452866 (Methods of inhibiting angiogenesis with fragments and homologs of troponin subunit 1) is held by Alseres Pharmaceuticals, Inc.. Status: granted. Granted Nov 18, 2008. Expires Nov 13, 2028 (2 years remaining) — relevant for patent-cliff and LOE planning.

Who owns US 7452866?

Alseres Pharmaceuticals, Inc. is listed as the applicant in USPTO PatentsView records indexed by NovaPharmaNews. We track 36 pharmaceutical patents for this assignee.

When does US 7452866 expire?

Our index shows an expiration date of Nov 13, 2028 (2 years from today). Confirm material dates against USPTO, FDA Orange Book, or qualified counsel before contractual decisions.